Adaptive’s clonoSEQ franchise is executing strongly, but a 12.6x sales valuation, insider selling, dilution, and separation risk create asymmetric downside despite compelling MRD growth.
Overview
Adaptive Biotechnologies commercializes immune-receptor sequencing through two segments: MRD diagnostics, centered on clonoSEQ, and Immune Medicine, focused on target discovery and data licensing. MRD represented 92% of Q2 2026 revenue, while Immune Medicine contributed 8%. clonoSEQ’s FDA clearance, sensitivity of 1 in 1,000,000 cells, NCCN support, reimbursement covering more than 300 million lives, and integrations across 173 major accounts give the company a leading position in hematologic MRD testing. Q2 revenue was **$71.6 million**, up 21.5%-30.0% year over year and above the approximately $65.44 million consensus estimate. MRD revenue rose 33% to $66.2 million, clinical volume increased 43% to 36,111 tests, ASP rose 7% to $1,382, and MRD gross margin expanded to 72%. Management raised 2026 MRD revenue guidance to $268 million-$278 million and expects MRD gross margin above 70%. The balance sheet improved after replacing the OrbiMed liability with $345 million of zero-coupon notes, although dilution remains a risk. Despite strong operations and analyst targets of $22-$28, the stock trades at 12.6x trailing sales versus a 4.3x industry average, and the report views valuation as stretched. Near-term catalysts are further MRD execution and the planned business separation by year-end 2026.